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Abstract
Objective We estimated the use of prescribed analgesics and adjuvants among nursing home residents without cancer who
reported pain at their admission assessment, in relation to resident-reported pain severity.
Methods Medicare Part D claims were used to define 3 classes of analgesics and 7 classes of potential adjuvants on the 21st day
after nursing home admission (or the day of discharge for residents discharged before that date) among 180,780 residents with
complete information admitted between January 1, 2011 and December 9, 2016, with no cancer diagnosis.
Results Of these residents, 27.9% reported mild pain, 46.6% moderate pain, and 25.6% reported severe pain. The prevalence of
residents in pain without Part D claims for prescribed analgesic and/or adjuvant medications was 47.3% among those reporting
mild pain, 35.7% among those with moderate pain, and 24.8% among those in severe pain. Among residents reporting severe
pain, 33% of those ≥ 85 years of age and 35% of those moderately cognitively impaired received no prescription analgesics/
adjuvants. Use of all classes of prescribed analgesics and adjuvants increased with resident-reported pain severity, and the
concomitant use of medications from multiple classes was common.
Conclusion Among nursing home residents with recognized pain, opportunities to improve the pharmacologic management of
pain, especially among older residents, and those living with cognitive impairments exist.
Keywords Nursing homes . Pain . Analgesics . Pain severity
Introduction
In the USA, there are ~ 1.7 million certified nursing home
beds [1]. For the residents who live in this healthcare setting,
pain is a common occurrence [2, 3]. If not treated appropri-
ately, pain may be associated with complications such as de-
pression, decreased social engagement, increased healthcare
utilization and costs, increased functional limitations, and
poor treatment outcomes [4–6]. The effective management
of pain is key to improving or maintaining the quality of life
of older adults.
In older adults, pharmacological treatment of pain can be
challenging due to age-related physiologic changes,
polypharmacy, and multimorbidity that may increase the risk
of adverse events [7]. Cognitive and sensory impairments in
old age also contribute to the inability of patients to effectively
communicate about their pain with health professionals,
which can negatively influence the types and intensity of treat-
ments that are provided [8, 9]. Furthermore, uncertainty re-
mains about the long-term safety and efficacy of common
analgesics, and a lack of knowledge about both the cause of
Keypoints
• Nursing home residents commonly experience pain.
• Medication management of pain could be improved as one in four
residents in severe pain received no pain medications or adjuvants to
pain medications.
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common pain syndromes [10] and the effectiveness of inter-
ventions to improve pain management [11].
Previously, we have shown that non-malignant pain recog-
nition and management in nursing homes is sub-optimal, with
up to one quarter of residents with daily pain not receiving any
analgesics for treatment [12–14], despite clinical practice
guidelines [15]. Using a national database of nursing home
residents (2011–2016), this study aimed to provide a contem-
porary description of prescription analgesic and adjuvant use
by pain severity among nursing home residents, to estimate
the prevalence of lack of prescription analgesic use across
levels of pain severity, and to identify factors associated with
lack of prescription analgesics and/or adjuvants for residents
with reported pain.
Methods
This study was approved by the University of Massachusetts
Medical School Institutional Review Board.
Sample selection
We used the Minimum Data Set 3.0 [16, 17]. which is a valid
and reliable tool completed by nursing home staff on virtually
every nursing home resident in the USA. Used for research
purposes [18], it includes a comprehensive admission assess-
ment information of sociodemographics, active clinical diag-
noses, and measures of functional [19] and cognitive status
[20]. Supplemental Table 1 provides a detailed description of
the sample selection.
Pain medications
Although the effectiveness of non-pharmacological ap-
proaches to pain management is recognized [21], phar-
macological approaches are the most commonly used to
treat pain in older adults [4]. We focused on the use of
analgesics or adjuvant medications for pain. We devel-
oped an expansive list of potential analgesics and adju-
vants guided by trusted resources [15, 22] and reviewed
by an expert in geriatric pharmacotherapy (AH). We
categorized prescription analgesics as short-acting opi-
oids (e.g., hydrocodone), long-acting opioids (e.g., fen-
tanyl patches), and non-opioid analgesics (e.g., acet-
aminophen not in cold preparations or other combina-
tions, celecoxib). We categorized prescription adjuvants
into 7 categories: gabapentinoids, other anticonvulsant
adjuvants (e.g., carbamazepine), SNRI antidepressants
(e.g., duloxetine), tricyclic antidepressants (e.g., amitrip-
tyline), muscle relaxants (e.g., clonazepam), systemic
glucocorticoids (e.g., prednisone), and lidocaine patches.
Residents with prescriptions with a day’s supply
covering the index date were considered users of that
medication. We then determined which classes of med-
ications were used alone, or in combination with other
classes of prescribed analgesics and/or adjuvants on the
index date.
Pain severity
TheMDS 3.0 was changed significantly in October 2010 [23],
with more opportunities for the “resident’s voice” to be heard
[24]. Residents had documented pain in the lookback window
of 5 days, and a self-assessment of pain severity, by one of two
methods: a numeric pain intensity rating (J06a: “Please rate
your worst pain over the last 5 days on a zero to ten scale, with
zero being no pain and ten as the worst pain you can imag-
ine.”), or a verbal descriptor scale (J06b: “Please rate the in-
tensity of your worst pain over the last 5 days: mild; moderate;
severe; very severe, horrible.”). Pain intensity ratings from 0
to 4 were tabulated with “mild” pain, pain intensity ratings
from 5 to 7 were tabulated with “moderate” pain, and pain
intensity ratings from 8 to 10 were tabulated with “severe”
pain, as were residents who reported “very severe, horrible”
pain. The MDS 3.0 provides the frequency of pain (i.e.,
rarely, occasionally, frequently, almost constantly),
whether or not pain affects sleep, and whether or not
pain limits day-to-day activities.
Covariates
We selected demographics (age group, sex, race/ethnicity, ad-
mission source, and dependence in activities of daily living
(ADL) [19]); potentially painful conditions from Section I
(e.g., surgical wounds, arthritis, diabetes); conditions that
may influence the communication of pain (e.g., cognitive
function score [20], Alzheimer’s or other dementias); and con-
ditions that maymodify the pain experience (e.g., depression).
Residents were classified as independent (ADL score 0–2),
modified dependence (score 3–4), or dependent (score 5–6).
Analytic strategy
With large sample sizes, trivial differences are often highly
statistically significant. Instead, we considered absolute differ-
ences greater than 5% to be noteworthy. We described the
distributions of key covariates and the use of monotherapy
and combinations of analgesics or adjuvants by level of pain
severity. The prevalence of a lack of prescribed analgesic/
adjuvant medications was estimated, stratified by pain sever-
ity. We used a linear modeling approach (logarithmic link
function with a Poisson distribution [25]) to estimate adjusted
prevalence ratios with 95% confidence limits, overall and
stratified by resident-reported pain severity.
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Results
Of 180,780 nursing home residents with documented pain
(Fig. 1), 27.9% reported mild pain, 46.6% moderate pain, and
25.6% severe pain. Among the 27.9% reporting mild pain,
47.3% had no Part D claims for analgesics or adjuvants; 22.7%
reported their pain frequency as rarely, 63.4% as occasionally,
10.7% as frequently, and 2.5% as almost constantly. Among the
46.6% reporting moderate pain, 35.7% had no Part D claims for
analgesic or adjuvants; 7.2% reported their pain frequency as
rarely, 55.9% as occasionally, 30.1% as frequently, and 6.2%
as almost constantly. Among the 25.6% reporting severe pain,
3.5% reported their pain frequency as rarely, 28.7% as occasion-
ally, 44.0% as frequently, and 22.9% as almost constantly, with
42.4% reporting that pain affects sleep and 52.8% indicating that
pain limits day-to-day activities. Among those reporting severe
pain, 24.8% had no Part D claims for analgesic or adjuvants.
While distributions of sex, race/ethnicity, activities of daily
living, and potentially painful conditions were similar across
level of pain severity, the distribution of age varied across
levels of pain severity with 44.6% of those in mild pain ≥
85 years of age whereas 34.0% of those in severe pain were
≥ 85 years of age (Table 1). The distribution of cognitive im-
pairment and active diagnoses of Alzheimer’s or other demen-
tias were different across levels of pain severity.
Short-acting opioids were commonly used (Table 2: 23.3%
among those with mild pain, 34.9% of those with moderate
pain, and 46.5% of those with severe pain). Regardless of the
level of pain severity, more than half receiving short-acting
opioids used them in combination with long-acting opioids,
non-opioid analgesics, and/or potential adjuvants. For exam-
ple, among short-acting opioid users in severe pain, 54% also
used potential adjuvants (25.2% of the whole sample), 20%
also used long-acting opioids (9.3% of the whole sample), and
14% used non-opioid analgesics (6.6% of the whole sample).
Non-opioid analgesics were used in 10.6% of those with mild
pain, 12.0% of those in moderate pain, and 13.2% of those in
severe pain. Potential adjuvant medications were used by
34.0% of those with mild pain and 48.0% of those with severe
pain, with gabapentinoids most common. Use of other anti-
convulsants was < 5%, regardless of level of pain severity.
SNRI antidepressants were used in 7.8% of residents with
mild pain, 9.6% of residents with moderate pain, and 12.3%
of residents with severe pain. Muscle relaxants were used in
5.4% of residents with mild pain, 6.4% in those with moderate
pain, and 7.8% of those reporting severe pain. No pain man-
agement strategies were documented for 19.8% of those in
mild pain, 12.0% of those in moderate pain, and 11.4% of
those in severe pain (Supplemental Table 2).
Table 3 shows that increasing pain severity was inversely
associated with lack of receipt of pharmacological pain medi-
cations (adjusted PRmoderate versus mild, 0.80 (95%CI 0.79–
0.82), adjusted PR severe versus mild, 0.60 (95% CI 0.59–



























Pain level Frequent/constant Affects sleep Limits day-to-day activity No analgesics/adjuvants
Proportion of pain affecting sleep, limiting daily activity, frequent/constant 
pain, and lack of analgesics/adjuvants, by level of pain severity
Mild SevereModerate
Fig. 1 Proportion of pain affecting sleep, limiting daily activity, frequent/constant pain, and lack of analgesics/adjuvants, by level o pain severity
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prescription medications included advanced age (adjusted PR
age ≥ 85 years versus 50–64 years, 2.00 (95% CI 1.93–2.08)),
moderate to severe cognitive impairment (adjusted PR, 1.20
(95% CI 1.17–1.22)), and having Alzheimer’s disease or other
dementias (adjusted PR, 1.14 (95% CI 1.12–1.17)). Estimates
of prevalence ratios were similar across the three levels of pain
severity (Supplemental Table 3).
Discussion
This study attempted to shed more light on the prescription
pain management strategies used in nursing home residents
with documented pain. This study did not include residents
without pain documented because they either did not experi-
ence pain in the 5 days preceding the MDS assessment or the
Table 1 Characteristics of newly admitted nursing home residents by resident-reported pain severity
Mild pain (n = 50,440) Moderate pain (n = 84,195) Severe pain (n = 46,145)
Percentage
Age group (years)
50 to 64 8.0 13.3 14.3
65 to 74 17.4 19.2 23.0
75 to 84 30.0 30.0 28.7
≥ 85 44.6 40.5 34.0
Men 26.4 24.9 23.8
Race/ethnicity*
Hispanic of any race(s) 4.6 4.7 4.0
Non-Hispanic, White 84.3 84.4 86.4
Non-Hispanic, Black 7.9 7.7 7.3
Admission source
Acute care hospital 42.1 48.6 51.9
Another nursing home or swing bed 14.5 13.2 12.1
Community 41.4 36.4 34.2
Another source 1.9 1.8 1.8
Activities of daily living
Independent 29.3 26.2 25.0
Modified dependence 56.4 57.4 57.1
Dependent 14.3 16.4 17.9
Potentially painful conditions
Heart failure 18.1 18.6 19.4
Respiratory failure 1.1 1.2 1.4
Surgical wounds or wound infections 6.5 9.0 9.7
Arthritis 35.5 38.0 39.7
Osteoporosis 17.0 18.1 18.8
Recent fracture 12.1 17.2 19.1
Mouth or face pain 1.5 1.7 2.5
Gastroesophageal reflux disorder 35.6 37.3 39.6
Ulcerative colitis, Crohn’s or irritable bowel 0.9 1.0 1.2
Swallowing disorder 3.3 3.2 3.5
High (2+) grade pressure ulcers 7.0 8.3 9.2
Foot problems 1.9 2.2 2.5
Other open lesions, or burns 1.7 1.8 2.0
Diabetes 31.5 33.0 35.2
Conditions that may influence the expression or recognition of pain
Cognitive Function Score
Cognitively intact 47.6 55.3 62.2
Mildly impaired 27.9 26.6 25.1
Moderately/severely impaired 24.4 18.0 12.8
Alzheimer’s or other dementia 35.3 27.6 21.7
Use of antipsychotics or hypnotics in past 7 days 21.4 21.4 23.1
Conditions that may modify the experience of pain
Depression 40.0 41.6 44.5
Anxiety disorder 24.5 26.1 29.2
*Few residents reported being non-Hispanic, American Indian/Alaska Native (0.8% of each pain category), non-Hispanic Asian (2.1% of those in mild
pain, 2.1% of those inmoderate pain, and 1.1% of those in severe pain), non-Hispanic Pacifica Islander (0.3% of each pain category), andmultiracial (0%
of those in mild pain, 0.1% of those in moderate pain, 0.1% of those in severe pain)
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pain management strategies used adequately controlled their
pain. We previously have noted that advanced age,
race/ethnicity, cognitive impairment, and dementia were in-
versely associated with persistent and intermittent pain [3,
12, 13], findings aligned with research by others [26, 27].
We demonstrated that among those who self-reported pain,
those reporting severe pain were less likely to be of advanced
age or to have cognitive impairment relative to those reporting
mild pain. Exploring whether stoicism in advanced age ex-
plains our findings, as has been reported by others [28], is
beyond the scope of our data. Concerns about MDS 3.0 pain
measures have been noted [29, 30]. The MDS 3.0 offered
significant improvements to capturing the resident experience
[23] and the vast majority of residents provide self-reported
information [24]. Continued efforts to improve the recognition
of pain in nursing home residents is warranted.








Prescription analgesics 33.4 46.4 59.2
Short-acting opioids 23.3 34.9 46.5
As monotherapy 10.5 14.1 15.8
In combination with long-acting opioids 2.1 4.6 9.3
In combination with non-opioid analgesics 3.1 4.9 6.6
In combination with potential adjuvants 10.6 17.1 25.2
Long-acting opioids 5.1 9.6 16.5
As monotherapy 1.3 1.9 2.6
In combination with non-opioid analgesics 0.6 1.3 2.3
In combination with potential adjuvants 2.9 5.8 10.3
Non-opioid analgesics 10.6 12.0 13.2
As monotherapy 4.5 3.9 3.1
In combination with potential adjuvants 4.4 5.6 7.2
Potential adjuvant prescription medications 34.0 40.5 48.0
Gabapentinoids 16.3 20.6 25.9
As monotherapy 5.7 5.5 5.0
In combination with prescription analgesics 7.7 12.2 17.8
Other anticonvulsant adjuvants 4.4 4.4 5.0
As monotherapy 1.8 1.3 1.1
In combination with prescription analgesics 1.5 2.2 3.0
SNRI antidepressants 7.8 9.6 12.3
As monotherapy 2.3 2.0 1.6
In combination with prescription analgesics 3.8 5.8 8.8
Tricyclic antidepressants 2.5 3.0 3.8
As monotherapy 0.8 0.7 0.5
In combination with prescription analgesics 1.1 1.7 2.6
Systemic glucocorticoids 4.6 5.8 7.1
As monotherapy 1.8 1.7 1.3
In combination with prescription analgesics 2.6 3.9 5.6
Muscle relaxants 5.4 6.4 7.8
As monotherapy 1.5 1.2 1.0
In combination with prescription analgesics 2.0 3.2 4.9
Lidocaine patches 3.7 5.4 6.9
As monotherapy 1.2 1.3 1.2
In combination with prescription analgesics 1.8 3.3 4.9
*The index date was either the 21st day after admission or the date of discharge for the ~ 15% of residents discharged from the nursing home in the first
21 days.We selected 21 days because themode ofMDS assessment completionwas 7 days after admission, giving nursing home staff ample opportunity
to respond to resident-reported pain
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Among nursing home residents with recognized pain, one in
four rated their pain as severe, with two-thirds of residents with
severe pain noting it occurred frequently or almost constantly.
Pain impacted residents’ sleep and limited residents’ ability to do
Table 3 Association between resident characteristics and lack of prescription analgesics/adjuvant medications among residents reporting pain
Prevalence of no prescription analgesics or















Moderate 100 0.80 (0.79–0.82)
Severe 100 0.60 (0.59–0.62)
Age group (years)
50 to 64 28.0 19.8 12.7 1.0
65 to 74 37.2 26.8 19.0 1.35 (1.30–1.40)
75 to 84 46.9 36.0 25.6 1.71 (1.65–1.78)
85 and older 55.1 43.7 33.2 2.00 (1.93–2.08)
Men 48.9 37.3 26.9 1.12 (1.10–1.14)
Race/ethnicity
Hispanic of any race(s) 47.2 37.3 27.7 1.03 (1.00–1.07)
Non-Hispanic, White 47.5 35.7 24.5 1.0
Non-Hispanic, Black 43.3 33.2 26.1 1.02 (0.99–1.05)
American Indian/Alaska Native alone 50.8 35.7 24.1 1.06 (0.97–1.15)
Asian alone 52.1 41.4 35.7 1.05 (0.99–1.11)
Pacific Islander alone 57.1 43.3 31.0 1.13 (1.00–1.27)
Multiracial 29.2 24.5 21.1 0.78 (0.54–1.14)
Admission source
Acute care hospital 50.1 38.1 26.6 1.03 (1.02–1.05)
Another nursing home or swing bed 40.9 29.5 21.3 0.93 (0.90–0.95)
Community 46.8 35.6 24.4 1.0
Another source 45.5 35.9 27.5 1.19 (1.12–1.26)
Activities of daily living
Independent 48.0 35.6 23.8 1.0
Modified dependence 47.8 36.3 25.4 0.97 (0.96–0.99)
Dependent 44.3 33.6 24.4 0.93 (0.90–0.95)
Potentially painful conditions
Heart failure 45.8 34.8 25.1 1.00 (0.98–1.02)
Respiratory failure 33.2 25.9 15.3 0.88 (0.81–0.96)
Surgical wounds or wound infections 43.6 33.9 25.0 1.04 (1.01–1.08)
Arthritis 42.5 31.7 22.0 0.82 (0.81–0.83)
Osteoporosis 46.6 34.3 23.1 0.93 (0.91–0.95)
Recent fracture 48.0 38.3 27.4 1.01 (0.99–1.04)
Mouth or face pain 47.6 33.4 25.9 1.01 (0.95–1.07)
Gastroesophageal reflux disorder 41.6 31.1 21.5 0.89 (0.88–0.91)
Ulcerative colitis, Crohn’s or irritable bowel 41.1 31.8 21.2 0.96 (0.89–1.04)
Swallowing disorder 48.5 38.3 27.5 1.04 (1.00–1.09)
High (2+) grade pressure ulcers 41.5 31.6 22.2 0.90 (0.88–0.93)
Foot problems 43.4 29.9 22.2 0.94 (0.88–0.99)
Other open lesions, or burns 47.0 34.1 20.7 0.97 (0.92–1.03)
Diabetes 43.0 32.4 22.7 0.96 (0.95–0.98)
Cognitive Function Score
Cognitively intact 42.3 31.4 21.7 1.0
Mildly impaired 48.8 38.1 27.6 1.10 (1.08–1.12)
Moderately or severely impaired 55.4 45.2 34.9 1.20 (1.17–1.22)
Alzheimer’s or other dementia 52.7 42.1 31.0 1.14 (1.12–1.17)
Use of antipsychotics or hypnotics in past
7 days
43.1 30.6 20.3 0.94 (0.92–0.96)
Conditions that may modify the experience of pain
Depression 39.2 28.1 18.8 0.78 (0.77–0.80)
Anxiety disorder 39.0 28.1 17.8 0.85 (0.83–0.86)
*Adjusted for all resident characteristics shown on the table
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day-to-day activities, and this increased with level of pain sever-
ity. Prescribed analgesics and adjuvants increased markedly with
pain severity for all groups of analgesics and adjuvants consid-
ered. However, 24.8% lacked prescription medications for pain
among those with identified severe pain. Residents aged ≥
85 years were least likely to receive prescribed analgesics or
adjuvants as compared with younger nursing home residents.
Cognitively impaired residents were more likely to endure their
painwithout the use of prescribed analgesics or adjuvants relative
to residents with mild cognitive impairment.
We found that in those with pain recognized and documented
by nursing home staff, lack of prescription analgesics was com-
mon, although less frequent with increased severity of pain. In
the USA, nursing homes are required by law (42 CFR §483.60)
to provide pharmaceutical services to meet the needs of each
resident [31]. Our findings documenting the extent to which
residents with documented pain had no Part D claims for pre-
scription analgesics, indicate that opportunities to enhance com-
pliance with this federal legislation are plentiful. Advanced age
and level of cognitive impairment were associated with de-
creased use of prescription pain medications, consistent with
what others have shown [32, 33]. The US Centers for
Medicare & Medicaid Services provided revised guidance for
meeting compliance in the evaluation and management of pain
in nursing home residents (i.e., F-Tag 309) in 2009. Such admin-
istrative initiatives appear to fall short. The extent to which these
findings have been influenced by federal efforts to address opioid
abuse is unknown [34]. Despite these efforts, improving pain
management in nursing home residents deserving of relief from
suffering and dignity in care [35] is imperative.
Consistent with previous research, we found that opioid use
was common [36], as was use of gabapentinoids [37, 38]. With
increased severity of pain, we see increased use of combination
therapies, suggesting that nursing homes often aggressively at-
tempt to manage pain. Our data do not permit us to evaluate the
extent to which the “right” pain medications or combination of
analgesics and/or adjuvants are given to the “right” residents at
the “right” time [39]. The Institute of Medicine’s report
“Relieving Pain in America” challenged researchers to imple-
ment a cultural transformation to better understand pain and its
management [40]. Foundational knowledge about how best to
support nursing homes to continue improving pain management
among those in life’s final chapter is needed.
Our data should be interpreted with caution as we were
unable to include those receiving Medicare managed care or
post-acute rehabilitation. Extrapolation of the findings from this
study to residents covered by managed care, or to residents
receiving post-acute rehabilitation services, should be undertak-
en with caution. Residents without Part D claims for analgesics
or adjuvants may have received non-prescription pain relief
and/or non-pharmacologic pain management. The MDS 3.0
lacks specific details about what non-pharmacological ap-
proaches or over the counter medications were used for pain.
The use of prescribed adjuvant medications (e.g., SNRI antide-
pressants, systemic glucocorticoids, anticonvulsants) may have
been for indications other than pain.
Conclusions
Many nursing home residents with pain receive no prescrip-
tion pharmacological management 3 weeks into their stay.
Those with cognitive impairment and those with advanced
age (≥ 85 years) had the greatest likelihood of no treatment.
In those whose pain is treated, use of combination analgesics
+/- adjuvants increased with severity of pain. Understanding
whether lack of prescription pharmacological management of
pain among those with moderate to severe pain at admission
reflects resident preference, clinician uncertainty given the
lack of a strong evidence base regarding risks and benefits in
nursing home residents, or other modifiable factors is warrant-
ed to provide “personalized” painmanagement to a population
deserving of improved quality of life [41].
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